Variants in the three-way intersections of credible sets predicetd to alter chromatin accessibility in brain cell types. by Daniela Fusco (10027975)

Subjects:

Genes associated by SMR to both BMI and at least one sMRI trait. by Daniela Fusco (10027975)

Subjects:

Genetic correlations between sMRI traits and BMI. by Daniela Fusco (10027975)

Subjects:

SMR reveals common molecular patterns. by Daniela Fusco (10027975)

Subjects:

Network of colocalized causal variants. by Daniela Fusco (10027975)

Subjects:

Epigenetic fine mapping and motif analysis for the TUFM locus. by Daniela Fusco (10027975)

Subjects:

Credible sets and evidence of colocalization. by Daniela Fusco (10027975)

Subjects:

Genetic correlation between BMI and 435 sMRI traits. by Daniela Fusco (10027975)

Subjects:

Percent viability and cytotoxicity of NHBE cells are significantly altered by PAA exposure. by Ellie S. Burns (21246537)

“…Percent viability significantly decreased with PAA concentration and between recovery times compared to controls. …”

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Demographic data of female participants (n = 30). by Vanessa Wellauer (18408477)

Subjects:

Results of physiological parameters. by Vanessa Wellauer (18408477)

Subjects:

Results of recovery parameters. by Vanessa Wellauer (18408477)

Subjects:

Raw data used for statistical analysis. by Vanessa Wellauer (18408477)

Subjects:

Schematic representation of the experimental protocol over time. by Vanessa Wellauer (18408477)

Subjects:

Pairwise comparisons of the intervention effects by time point for physiological parameters. by Vanessa Wellauer (18408477)

Subjects:

CONSORT flowchart of participants. by Vanessa Wellauer (18408477)

Subjects:

Pairwise comparisons of the intervention effects by time point for recovery parameter. by Vanessa Wellauer (18408477)

Subjects:

Participant retention flowchart. by Carolin Oetzmann (11397968)

Subjects: